When the FDA approved the authorization and a new approval mechanism of the sophisticated cancer screening test developed by researchers at Memorial Sloan Kettering Cancer Center, I immediately wondered what this would mean to the agency’s oversight of next-generation sequencing.
You see, the test, called MSK-IMPACT, uses next-generation sequencing to analyze hundreds of cancer genes and determine quickly whether a patient’s tumor carries clinically useful mutations. This screening also allows them to match individual patients with available therapies or clinical trials that will most benefit them.
Pretty neat, right? But the thing is, the Food and Drug Administration hasn’t finalized how it’s going to regulate these advanced in vitro diagnostics because the proposal released last year for next-generation sequencing is still in draft form.
It turns out I was asking the wrong question.
But at least I was asking the right people.
“This is really a clever sleight-of-hand in a way,” Carol Pratt, one of our board members, an FDA regulatory attorney with Lee & Hayes told me. “It appears that the FDA is announcing a new, low-burden regulatory pathway for IVD devices, when it is really about a voluntary ‘authorization’ process for LDTs.”
LDTs are laboratory-developed tests, which most next-generation sequence diagnostics are. There was so much discord over whether and how the FDA should regulate these diagnostics that the FDA pulled its proposed plan a year ago to give the incoming White House an opportunity to ponder it.
Jennifer Dickey, director of regulatory and quality for Personal Genome Diagnostics, told me, “FDA appears to be establishing a pathway to encourage developers of NGS-based LDTs serving oncology patients to submit their tests to be cleared for marketing.” Before joining the private sector, she worked at the FDA as a senior scientific reviewer in the molecular genetics branch of the agency’s office of in vitro diagnostics and radiological health.
Gail H. Javitt, an attorney with Epstein Becker Green in Washington who has published several scholarly articles on the regulation of NGS, told me the announcement raises a lot of questions, including what this means for LDTs. “FDA is currently exercising enforcement discretion over laboratory-developed tests. And yet FDA just cleared a laboratory-developed test for cancer.”
Javitt called me from the Personalized Medicine Coalition’s conference in Boston, where these same issues came up. My colleague Adrianne Appel, who covered the conference, reported the FDA will soon launch a program for certifying laboratories that develop diagnostic tests, in lieu of drafting rules for the tests themselves, an official said.
You have to subscribe to read that story, but you can read mine here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)